NextGen Office COVID 19 Announcements
Announcements:
12/18/2020 - On December 18, 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
12/11/2020 - On December 11, 2020, the U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S.
12/10/2020 - A Message About the COVID-19 Vaccine from NextGen Healthcare
In the days ahead, vaccine manufacturers are expected to receive final approval from the Food and Drug Administration (FDA) to begin distribution of the first COVID-19 vaccines to providers for administration to patients. Health IT vendors like NextGen Healthcare have a critical role to play in tracking and reporting vaccine administration. As part of its “Operation Warp Speed” initiative, the Department of Health and Human Services (HHS) has already engaged NextGen Healthcare and our industry colleagues to coordinate efforts.
Current Status
• We have received new vaccine and administration codes from our partner First Data Bank, which will be made available to our clients, along with instructions for setting up and using these codes in your software.
• Since these vaccines are the first of their kind, there are open questions about administration and reporting requirements. Once we receive answers to these questions, we will commence any necessary development work.
COVID-19 treatments that have been approved by the FDA for Emergency Use Authorization.
Oct 22, 2020
VEKLURY 100 mg - NDC ID: 61958290102
REMDESIVIR (EUA) 100 mg - NDC ID: 61958290101
REMDESIVIR (EUA) 100 mg/20 mL (5 mg/mL) - NDC ID: 61958290201
Nov 9, 2020
BAMLANIVIMAB (EUA) 700 mg/20 mL (35 mg/mL) - NDC ID: 00002791001
Nov 21, 2020
CASIRIVIMAB (REGN10933) (EUA) 300 mg/2.5 mL (120 mg/mL) NDC ID: 61755002400
IMDEVIMAB (REGN10987) (EUA) 300 mg/2.5 mL (120 mg/mL) NDC ID: 61755002500
COVID-19 vaccines that have been approved by the FDA for Emergency Use Authorization.
12/11/2020 - The Pfizer COVID-19 vaccine was approved for Emergency Use in the U.S.
Brand Name: PFIZER COVID19 VACC (UNAPPROV)
Vaccine Description: Pfizer-BioNTech COVID-19 Vaccine(PF) 30 mcg/0.3mL IM susp
CPT Code: 91300
CPT Code Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
CVX Code: 208
CVX Code Description: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose
Associated NDC IDs: 59267100001, 59267100002, 59267100003
12/18/2020 - The Moderna COVID-19 vaccine was approved for Emergency Use in the U.S.
Brand Name: MODERNA COVID19 VACC(UNAPPROV)
Vaccine Description: Moderna COVID-19 Vaccine (PF) 100 mcg/0.5mL IM susp
CPT Code: 91301
CPT Code Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
CVX Code: 207
CVX Code Description: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose
Associated NDC IDs: 80777027310, 80777027399
FAQ:
Q: When will the COVID-19 treatments and vaccines become available in NextGen Office?
A: The COVID-19 treatments and vaccines will be made available in the 12-2020 Drug Interaction Medication Update. Released! 12/11/2020.
Q: How will the COVID-19 treatments and vaccines get added to NextGen Office?
A: The Drug Interaction Medication Update will contain the data and will need to be applied to your environment.
Q: Will a NextGen Office Patch need to be applied?
A: At this time, no patches need to be applied. As of 12/9/2020.
Q: How will we be reporting to the appropriate government agency when we vaccinate patients?
A: Since these vaccines are the first of their kind, there are open questions about administration and reporting requirements. Once we receive answers to these questions, we will commence any necessary development work.
Q: How will we track which patients have received a COVID-19 vaccine?
A: The COVID-19 vaccine will be documented in the Immunization Module in the patient's chart.
Q: Can we generate patient reports inNextGen Office that would indicate who has had and has not had a COVID-19 vaccine?
A: The Report Writer in Enterprise EHR provides the ability to create ad-hoc reports. No Crystal Reports as of 12/9/2020.
Q: Where can I find the VIS Sheets for the COVID-19 vaccine?
A: VISs are required only if a vaccine is added to the Vaccine Injury Table. Optional VISs may be produced, but only after a vaccine has been licensed (e.g., such as with zoster vaccines). Plans for developing a VIS for COVID-19 vaccine are not known at this time but will be communicated as additional information becomes available. The FDA has provided a Fact Sheet for recipients and caretakers. As of 12/16/2020.
Q: Will I need to add the COVID-19 CPT4 codes to the CPT4 codes list in File Maintenance?
A: Yes, the COVID-19 CPT4 codes have not been included in a CPT4 code update so the codes will need to be manually entered. As of 12/9/2020.
Q: Will I need to create a Service Item for the COVID-19 CPT4 codes in File Maintenance?
A: Yes, the COVID-19 codes will need to be added to the Service Items Library. As of 12/9/2020.
Q: Will I need to create a Service Item for the COVID-19 CPT4 codes in File Maintenance?
A: Yes, the COVID-19 codes will need to be added to the Service Items Library. As of 12/9/2020.
Q: What are the CVX codes and CPT4 codes for the COVID-19 Vaccines?
A: PFIZER COVID19 VACCINE
CPT Code: 91300
CVX Code: 208
MODERNA COVID19 VACCINE
CPT Code: 91301
CVX Code: 207
Q: What vaccine administration billing codes are used when administering the COVID-19 vaccine?
A: A different vaccine admin billing code will be needed for each scheduled dose
Pfizer 1st Dose: 0001A ADM SARSCOV2 30MCG/0.3ML 1ST
Pfizer 2nd Dose: 0002A ADM SARSCOV2 30MCG/0.3ML 2ND
Moderna 1st Dose: 0011A ADM SARSCOV2 100MCG/0.5ML1ST
Moderna 2nd Dose: 0012A ADM SARSCOV2 100MCG/0.5ML 2ND
Q: When a COVID-19 vaccine is administered in the Immunization Module will the admin billing code automatically default?
A: No, the admin billing code for the COVID-19 vaccine will need to be manually select from the Admin CPT4 drop down at the time the vaccine is administered. As of 12/9/2020.
Q: Has a COVID-19 vaccine been approved for use in the U.S.?
A: Yes, the Pfizer COVID-19 vaccine was approved for emergency use only in the U.S. on 12/11/20 and the Moderna COVID-19 vaccine was approved for emergency use only in the U.S. on 12/18/20.
Q: How many doses will be needed for the Pfizer COVID-19 vaccine?
A: 2 doses of the vaccine are recommended for a 95% immunity from the virus.
Q: How far apart should the Pfizer COVID-19 vaccine doses be taken?
A: The Pfizer-BioNTech COVID-19 Vaccine is a suspension for intramuscular injection administered as a series of two doses (0.3 mL each) 3 weeks apart.
Q: What age group does the FDA recommend for the Pfizer COVID-19 vaccine?
A: The Pfizer COVID-19 vaccine is recommended for patients 16 and older.
Q: How many doses will be needed for the Moderna COVID-19 vaccine?
A: The Moderna COVID-19 Vaccine is administered as a 2-dose series
Q: How far apart should the Moderna COVID-19 vaccine doses be taken?
A: 1 month (28 days)
Q: What age group does the FDA recommend for the Moderna COVID-19 vaccine?
A: 18 years of age and older
Click below to schedule a NextGen Office Demo
